If the "Interim Results" at the two other dose concentrations (20 mg & 40 mg) from the 207 study (pharmacokinetic study) uncovered "some" potential safety issues related to the higher concentrations, would GENR management be required to halt the current enrollment of other PII studies?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.